

# CITATION REPORT

List of articles citing

## Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

DOI: 10.2147/dddt.s267404

Drug Design, Development and Therapy, 2021, 15, 2401-2415.

**Source:** <https://exaly.com/paper-pdf/81032195/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
15	BCMA in Multiple Myeloma-A Promising Key to Therapy. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
14	Associa� Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2021</b> , 43 Suppl 2, S30-S34	1.6	0
13	A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.. <i>ChemMedChem</i> , <b>2022</b> , e202200032	3.7	3
12	Cardiovascular Complications of Modern Multiple Myeloma Therapy: Analysis of FDA Adverse Event Reporting System.		0
11	Kidney Effects by Alternative Classes of Medicines in Patients and Relationship to Effects in Nonclinical Toxicity Studies. <i>Toxicologic Pathology</i> , 019262332211004	2.1	0
10	An update on novel multiple myeloma targets. <i>Expert Review of Hematology</i> ,	2.8	0
9	Cardiovascular Complications of Modern Multiple Myeloma Therapy: A Pharmacovigilance Study.		0
8	Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma.		0
7	Belantamab mafodotin induces immunogenic cell death within 24 hours post administration in newly diagnosed multiple myeloma patients.		0
6	Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).		0
5	Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets. <b>2023</b> , 21, 24		0
4	Management of Belantamab Mafodotin-Associated Keratopathy With Rigid Gas-Permeable Corneal Contact Lenses. <b>2023</b> , Publish Ahead of Print,		0
3	Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. <b>2023</b> , 16, 415		0
2	The Effect of Belantamab Mafodotin on Primary Myeloma-Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells. <b>2023</b> , 24, 5303		0
1	Current Prospects and Clinical Status of Microalgae Derived Chemotherapeutics.		0